IP Library Granted Patent US 10,696,731
Granted Patent B2
US 10,696,731 · App. 15/670,217 · Granted Jun 30, 2020

Oligopeptide-free cell culture media

Inventors: Leopold Grillberger (Vienna, AT); Manfred Reiter (Vienna, AT); Wolfgang Mundt (Vienna, AT); Artur Mitterer (Orth/Donau, AT)
Assignees: Baxalta GmbH; Baxalta Incorporated
C07K14/755C12N5/005C12N5/0018C12N7/00C12N2500/05C12N2500/10C12N2500/20C12N2500/24C12N2500/32C12N2500/38C12N2500/46C12N2500/50C12N2710/24151
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,696,731
App. No.
15/670,217
Granted
Jun 30, 2020
Kind
B2
Abstract

The present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine and to methods for cultivating cells in said oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine. The invention also relates to methods for expressing at least one protein in a medium comprising at least 0.5 mg/L of a polyamine and to methods for producing at least one virus in a medium comprising at least 0.5 mg/L of a polyamine.

Claims (18)

1. A method for increasing the expression of a recombinant protein in a cell culture, the method comprising culturing mammalian cells that express a recombinant protein in a protein-free medium that does not comprise oligopeptides, wherein the medium comprises DMEM:HAM's F12 (1:1) basal medium, inorganic salts, amino acids, vitamins, ornithine, and putrescine at a concentration of at least 1 mg/L, and wherein the medium is supplemented with Fe(II) and Cu(II) at an amount greater than the amount in basal DMEM: HAM's F12 (1:1).

2. The method according to claim 1 , wherein the medium is supplemented with L-glutamine, ascorbic acid, ethanolamine, sodium selenite, and a non-ionic surfactant.

3. The method according to claim 1 , wherein the medium is supplemented with L-Asparagine, L-Cysteine, L-Cystine, L-Proline, and L-Tryptophan.

4. The method according to claim 1 , wherein the medium comprises putrescine at a concentration of from about 1.0 mg/L to about 20 mg/L.

5. The method according to claim 1 , wherein the medium further comprises one or more from the group consisting of cadaverine, spermidine, spermine, and agmatine.

6. The method according to claim 1 , wherein the medium further comprises spermine.

7. The method according to claim 1 , wherein the medium comprises a buffer substance.

8. The method according to claim 7 , wherein the buffer substance is selected from one or more of sodium bicarbonate, antioxidants, stabilizers, or protease inhibitors.

9. The method according to claim 1 , wherein the recombinant protein is selected from the group of coagulation factor VII, coagulation factor VIII, coagulation factor IX, vWF, ADAMTS13, and furin.

10. The method according to claim 8 , wherein the recombinant protein is coagulation factor VIII.

11. The method according to claim 8 , wherein the recombinant protein is vWF.

12. The method according to claim 1 , wherein the mammalian cells are CHO cells, 293 cells or BHK cells.

13. The method according to claim 1 , wherein the mammalian cell/protein combination is selected from the group consisting of CHO cells/coagulation factor VIII, CHO cells/coagulation factor VII, CHO cells/ADAMTS13, CHO cells/furin, 293 cells/coagulation factor IX.

14. The method according to claim 13 , wherein the mammalian cell/protein combination is CHO cells/coagulation factor VIII.

15. The method according to claim 1 , wherein the putrescine is synthetically produced.

16. The method according to claim 1 , wherein the putrescine originates from a source other than a protein hydrolysate.

17. The method according to claim 1 , wherein the medium is chemically defined.

18. The method according to claim 1 , wherein the mammalian cells are cultured by a method selected from the group of batch-cultivation, feed-batch-cultivation, perfusion-cultivation and chemostat-cultivation.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0005 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2017
From: GRILLBERGER, LEOPOLD; REITER, MANFRED; MUNDT, WOLFGANG; MITTERER, ARTUR
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 043725/0483 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2017
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 044046/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2017
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 044046/0356 →